Abstract |
The continuous growth of tumors depends on the altered regulation of the cell cycle, which is in turn modulated by signals from growth factors and their receptors. Blockade of insulin-like growth factor ( IGF)-I and IGF-IR by antisense or dominant negative plasmid transfection can suppress tumorigenicity and induce regression of established tumors. We have constructed two recombinant adenoviruses: an adenovirus expressing truncated IGF-IR (ad-IGF-IR/950) with an engineered stop codon at amino acid residue 950, and an adenovirus expressing the soluble extracellular domain of IGF-IR (ad-IGF-IR/482) with an engineered stop codon at amino acid residue 482. Ad-IGF-IR/950 produces a defective receptor with an intact alpha subunit and a defective beta subunit lacking the tyrosine kinase domain. Dominant negative inhibition results from competition of the defective receptor with normal IGF-IR subunits, or the competition with normal IGF-IR for ligand by the soluble receptor. We were able to show here that ad-IGF-IR/950 induced the increased expression of IGF-IR on the cell surface and ad-IGF-IR/482 induced the secretion of the soluble fragment of IGF-IR. The transduction of both ad-IGF-IR/950 and ad-IGF-IR/482 could blunt the growth-stimulatory effect of IGF-I on human lung cancer cell lines. Both ad-IGF-IR/950 and ad-IGF-IR/482 effectively blocked IGF-I-induced Akt kinase activation. Intratumoral injection of ad-IGF-IR/482 virus showed significant growth suppression in established lung cancer xenografts. These findings suggest that these ad-IGF-IR/dn (950, 482) have the potential to be effective and practical cancer gene therapy strategies.
|
Authors | Choon-Taek Lee, Kyung-Ho Park, Yasushi Adachi, Ja Young Seol, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Keith Coffee, Mikhail M Dikov, David P Carbone |
Journal | Cancer gene therapy
(Cancer Gene Ther)
Vol. 10
Issue 1
Pg. 57-63
(Jan 2003)
ISSN: 0929-1903 [Print] England |
PMID | 12489029
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Proto-Oncogene Proteins
- Recombinant Proteins
- Insulin-Like Growth Factor I
- Receptor, IGF Type 1
- AKT1 protein, human
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins c-akt
- Thymidine
|
Topics |
- Adenocarcinoma, Bronchiolo-Alveolar
(genetics, metabolism, therapy)
- Adenoviridae
(genetics, metabolism)
- Animals
- Carcinoma, Large Cell
(genetics, metabolism, therapy)
- Cell Division
(drug effects)
- Colony-Forming Units Assay
- Female
- Genes, Dominant
(physiology)
- Genetic Therapy
(methods)
- Humans
- Insulin-Like Growth Factor I
(metabolism)
- Lung Neoplasms
(genetics, metabolism, therapy)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins
(metabolism)
- Proto-Oncogene Proteins c-akt
- Receptor, IGF Type 1
(genetics, metabolism)
- Recombinant Proteins
(genetics, metabolism)
- Sequence Deletion
- Thymidine
(metabolism)
- Transfection
- Tumor Cells, Cultured
|